Publications by authors named "S P Treon"
Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Constantine S Mitsiades Nicholas Mitsiades Vassiliki Poulaki Robert Schlossman Masaharu Akiyama Steven P Treon
Oncogene
November 2024
Article Synopsis
- Covalent Bruton's tyrosine kinase-inhibitors (cBTK-i) are effective in treating MYD88-mutated Waldenstrom's macroglobulinaemia by inhibiting key signaling pathways that promote tumor growth.* -
- BTK mutations can lead to treatment resistance by reactivating ERK1/2, which causes increased inflammatory cytokine production and helps BTK wild-type tumor cells survive.* -
- Pirtobrutinib, a non-covalent BTK-inhibitor, has been shown to successfully block damaging ERK1/2 activity and can overcome resistance in MYD88 lymphoma cells with mutated BTK.*
Article Synopsis
- The ASPEN study is a Phase III clinical trial that compares the effectiveness of two drugs, zanubrutinib and ibrutinib, in treating patients with Waldenström macroglobulinemia (WM).
- A total of 201 patients participated, with 102 receiving zanubrutinib and 99 receiving ibrutinib, and the outcomes were evaluated using patient-reported questionnaires.
- Results indicated that zanubrutinib led to better improvements in health-related quality of life, particularly regarding symptoms like diarrhea and nausea/vomiting, as well as overall physical functioning and fatigue in patients who achieved a very good partial response to treatment.